Quantcast

Latest Amgen Inc. Stories

2011-03-21 08:31:00

CHICAGO, March 21, 2011 /PRNewswire/ -- Seven Summits Research issues critical PriceWatch Alerts for COP, AMGN, NYX, NTAP, and FL. To see what our analysts have discovered about these stocks read the Seven Summits Strategic Investments' PriceWatch Alerts at http://www.iotogo.com/s/032111A (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: ConocoPhillips (NYSE: COP), Amgen Inc. (Nasdaq: AMGN), NYSE...

2011-03-17 21:02:25

Novel mechanistic approach to directly modulating muscle contractility may represent a promising strategy to treat systolic heart failure Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the publication of preclinical research in the March 18, 2011 issue of the journal Science regarding the activation of cardiac myosin by an investigational drug candidate, omecamtiv mecarbil, and the potential therapeutic role that this novel mechanism may play for patients with systolic heart...

2011-01-31 10:00:00

SAN FRANCISCO, Jan. 31, 2011 /PRNewswire/ -- Global Real Estate Consultants has helped Boehringer Ingelheim to strengthen their global presence with a new facility in Fremont. Global Real Estate Consultants was retained by Boehringer Ingelheim to provide insight and transparency in the Fremont commercial real estate market specifically related to their purchase of Amgen Inc's 350,000 sq. ft. state-of-the-art manufacturing facility with pilot plant and process development labs. "We looked...

2011-01-24 15:08:00

THOUSAND OAKS, Calif., Jan. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.17 for the fourth quarter of 2010, an increase of 11 percent compared to $1.05 for the fourth quarter of 2009. Adjusted net income increased 4 percent to $1,103 million in the fourth quarter of 2010 compared to $1,065 million in the fourth quarter of 2009. Full year 2010 adjusted EPS were $5.21 versus $4.91 in 2009, a 6 percent increase. Full year 2010 adjusted...

2011-01-18 15:45:00

THOUSAND OAKS, Calif. and INGELHEIM, Germany, Jan. 18, 2011 /PRNewswire/ -- Amgen Inc. (Nasdaq: AMGN) and Boehringer Ingelheim today announced they have signed an agreement under which Boehringer Ingelheim will acquire Amgen's rights in and substantially all assets at Amgen's Fremont California development and manufacturing facility. The transaction has been approved by the board of directors of each company and is expected to close in March of this year. The Amgen Fremont facility...

2010-12-05 15:30:00

ORLANDO, Fla., Dec. 5, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events. The complete data,...

2010-11-18 18:41:00

THOUSAND OAKS, Calif., Nov. 18, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved XGEVA(TM) (denosumab), the first and only RANK Ligand inhibitor for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. XGEVA was approved following a 6 month priority review by the FDA, a designation reserved for drugs that offer major advances in treatment or provide a...

2010-11-10 16:04:00

THOUSAND OAKS, Calif., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from the first open-label study to compare Nplate(® )(romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patients with chronic immune thrombocytopenia (ITP). The study results, which were published today in the New England Journal of Medicine (NEJM), show that both the incidence of treatment failure and need...

2010-11-06 16:00:00

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., Nov. 6, 2010 /PRNewswire/ -- Amgen Inc. (Nasdaq: AMGN), Pfizer Inc. (NYSE: PFE) and world-class professional golfer Phil Mickelson, have entered into a partnership to share Phil's experience with his diagnosis of psoriatic arthritis and treatment with Enbrel® (etanercept), and to encourage patients with similar symptoms to visit their doctor for proper assessment and care. "This partnership with Amgen and Pfizer is...

2010-10-25 15:12:00

THOUSAND OAKS, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) reported revenue unchanged for the third quarter of 2010 at $3,816 million versus $3,812 million for the third quarter of 2009. Adjusted net income decreased 14 percent to $1,313 million for the third quarter of 2010 compared to $1,518 million for the third quarter of 2009. The decrease in adjusted net income was driven by unusually low research and development (R&D) costs and favorable tax settlements in...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.